ReviewViruses2022
Hepatitis C: Standard of Treatment and What to Do for Global Elimination.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Unveiling disparities: a study on hepatitis C awareness among medical professionals in the southeast coastal regions of China.BMC infectious diseases · 2026Article
- China data on the burden of alcohol-associated liver cancer from 1990 to 2021: a systematic analysis from the global burden of disease study 2021.Ecancermedicalscience · 2026Article
- Mechanistic and Kinetic Insights into the Acylation Reaction of Hepatitis C Virus NS3/NS4A Serine Protease with NS4B/5A Substrate.Biomolecules · 2025Article
- Global and Chinese burden of non-alcoholic fatty liver disease in chronic liver disease: Findings from the Global Burden of Disease Study 2021.Chinese medical journal · 2025Article
- Detection of anti-HCV antibodies in the clinical classification and epidemiological surveillance of HCV infection.Molecular biology reports · 2025Review
- Prevalence of Hepatitis C in the Emilia-Romagna Region of Italy: Population-Wide Screening.Viruses · 2025Article
- Clinically Important Decrease in Liver Stiffness Following Treatment for Hepatitis C: Outcome of the TraP HepC Nationwide Elimination Program.Journal of clinical medicine · 2025Article
- Integrative analysis of serum proteomics and transcriptomics in hepatitis C.Virology journal · 2025Article
- Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.BMJ open gastroenterology · 2025Article
- Global burden of hepatitis C virus infection related to high body mass index and future forecast: an analysis based on the global burden of disease study 2021.Frontiers in public health · 2025Article
- N-arylpyrimidinamine (NAPA) compounds are broadly acting inhibitors of human cytomegalovirus infection and spread.Antiviral research · 2025Article
- What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study.Frontiers in oncology · 2025Article
- [Study on hepatitis C intervention measures to improve the referral, treatment, and cure rate in hospitals].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- HCV Treatment Outcomes in PWID: Impact of Addiction History on SVR12.Microorganisms · 2024Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management.Clinics and practice · 2024Review
- Community Versus Facility-Based Services to Improve the Screening of Active Hepatitis C Virus Infection in Cambodia: The ANRS 12384 CAM-C Cluster Randomized Controlled Trial-Protocol for a Mixed Methods Study.JMIR research protocols · 2024Article
- Primary healthcare as a strategy for eliminating hepatitis C: the METRIC toolkit.Primary health care research & development · 2024Article
- A Machine Learning-Based Mortality Prediction Model for Patients with Chronic Hepatitis C Infection: An Exploratory Study.Journal of clinical medicine · 2024Article
- Review
- Prevention in Hepatology.Journal of personalized medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus infection has a substantial effect on morbidity and mortality worldwide because it is a cause of cirrhosis, hepatocellular carcinoma, liver transplantation, and liver-related death. Direct acting antiviral drugs available today have high efficacy and excellent safety and can be used in all patients with clinically evident chronic liver disease and in groups that demonstrate risk behaviors to reduce the spread of infection. The Global Health Strategy of WHO to eliminate hepatitis infection by 2030 assumes "a 90% reduction in new cases of chronic hepatitis C, a 65% reduction in hepatitis C deaths, and treatment of 80% of eligible people with HCV infections". In this review effective models and strategies for achieving the global elimination of HCV infection are analyzed. The screening strategies must be simple and equally effective in high-risk groups and in the general population; fast and effective models for appropriate diagnosis of liver disease are needed; strategies for direct acting antiviral drug selection must be cost-effective; linkage to care models in populations at risk and in marginalized social classes must be specifically designed and applied; strategies for obtaining an effective vaccine against HCV infection have yet to be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.